Efficacity and Safety of Metformin XR in CKD Stage 1 to 3

NCT02895750•Centre Hospitalier Universitaire, Amiens

Summary

There is limited data availability on effect of Metformin XR on 24-h plasma glucose, and there is no available data in chronic kidney disease (CKD). The planned study aims to provide data on glucose plasma level in relation to metformin plasma level in Diabetes Type II patients.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Type 2 diabetes patients aged between 18 and 80 years requiring metformin (and any other antidiabetic treatment)

Exclusion Criteria

•Pregnancy and lactation
•Hyperlactatemia (\> 2.5 mmol/L)
•No creatinine levels available since 3 months
•Severe hepatic insufficiency
•No liver function parameters available
•Need of investigation with iodized contrast media
•Hypersensitivity to metformin

Locations (1)

CHU Amiens Picardie

Amiens, France

Key Dates

Start Date

August 30, 2017

Primary Completion Date

January 8, 2022

Completion Date

October 10, 2022

Last Updated

September 19, 2025

Enrollment

ACTUAL participants

Conditions

Renal Insufficiency, Chronic

Interventions

Metformin

DRUG

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

NCT06314503

Renal Insufficiency, ChronicKidney Failure, Chronic+1 more

View study

RECRUITINGPHASE1/PHASE2

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

NCT06863194

Kidney Disease, ChronicRenal Insufficiency, Chronic+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacity and Safety of Metformin XR in CKD Stage 1 to 3

Inclusion Criteria

Exclusion Criteria

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

Effects of Exogenous Ketosis on Proteinuria and Renal Function

Penn Produce Prescription and Chronic Kidney Disease Study

Acute Kidney Injury Genomics and Biomarkers in TAVR Study

Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP